Human genetic studies have implicated a wide vari ety of immune genes in the pathophysiology of auto immune and inflammatory diseases. These studies have suggested a role for aberrant immune cell activation in these diseases and have guided recent investigations into the molecular mechanisms underlying disease pathogenesis. From the many polymorphisms ana lysed, several genes -including the gene encoding the antiinflammatory signalling molecule A20 (TNFAIP3) -have been linked to susceptibility to multiple dis eases. The products of these genes are likely to regulate crucial steps in immune cell homeostasis and should be attractive targets for targeted therapies.
Perhaps the bestcharacterized molecular pathway for triggering immune cell activation is the canonical nuclear factorκB (NFκB) signalling pathway, which leads to the transcription of numerous proinflammatory and cellsurvival genes 1 . Excessive NFκB signalling in multiple cell types has been linked to both human and experimental inflammatory diseases, and to malignant diseases. For example, dysregulated NFκB signals underlie the pathophysiology of common subtypes of B cell lymphoma and myeloma 2 , as well as colon carcino genesis 3 . Therefore, determining how NFκB signals are normally restricted is crucial both for understanding the pathophysiology of these diseases and for devising therapeutic strategies.
The NFκB signalling cascade is prominently regulated by ubiquitylation, a process that can gener ate a series of posttranslational modifications that direct proteins towards distinct biological fates 4 . For example, the attachment of K48linked polyubiquitin chains targets proteins for proteasomal degradation, whereas the attachment of K63linked polyubiquitin chains can result in the recruitment of downstream signalling molecules that propagate signals 4, 5 . Thus, the precise synthesis, recognition and degradation of diverse types of ubiquitin chain must be specified by ubiquitin ligases, ubiquitinbinding proteins and deubiquitylating enzymes (DUBs), respectively, to ensure the proper regulation of intracellular signal ling pathways. The functions of ubiquitylation in cell signalling have recently been described in several excellent reviews [4] [5] [6] . The ubiquitinmodifying enzyme A20 has emer ged as a potent and unusually complex regulator of ubiquitindependent signals. A20 is a pleiotropically expressed cytoplasmic protein, the expression of which is regulated at both the transcriptional and the post transcriptional level. Induced by NFκBdependent sig nals, A20 in turn restricts the duration and intensity of signalling by several molecules involved in the NFκB pathway. Hence, the induction of A20 expression con stitutes a negative feedback loop for NFκB signalling
Ubiquitylation
The covalent attachment of single ubiquitin molecules or ubiquitin chains to proteins to regulate their interactions with proteasomal components and other proteins. Protein ubiquitylation occurs in three enzymatic steps that require a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3), respectively. The ligase catalyses the formation of an isopeptide bond between the carboxyl terminus of ubiquitin and an amino group belonging to a lysine residue of the target protein.
A20: linking a complex regulator of ubiquitylation to immunity and human disease
Averil Ma and Barbara A. Malynn Abstract | A20 (also known as TNFAIP3) is a potent anti-inflammatory signalling molecule that restricts multiple intracellular signalling cascades. Recent studies in three general areas have converged to highlight the clinical and biological importance of A20. First, human genetic studies have strongly linked polymorphisms and mutations in the gene encoding A20 to inflammatory, autoimmune and malignant diseases. Second, studies in gene-targeted mice have revealed that A20 regulates multiple immune cell functions and prevents experimental diseases that closely mimic human conditions. Third, biochemical studies have unveiled complex mechanisms by which A20 regulates ubiquitin-dependent nuclear factor-κB and cell-survival signals. Taken together, these studies are revealing the importance of A20-mediated regulation of ubiquitin-dependent signalling in human disease. In addition, posttranslational modifications of A20 -including phosphorylation, protein cleavage, glycos ylation and ubiquitylation -may serve to support or restrict its activity 8, 9, 10 . A20 restricts NFκB signalling downstream of tumour necrosis factor receptor 1 (TNFR1), CD40, Tolllike receptors (TLRs), NODlike receptors (NLRs) and the interleukin1 receptor (IL1R) [11] [12] [13] [14] [15] [16] [17] [18] [19] . A20 also promotes cellsurvival signals, adding another dimension to its ability to regulate dynamic immune responses 14 . Of note, the ability of A20 to inhibit cell death may be independ ent of its role in restricting NFκB signalling, as decreased NFκB signalling is typically associated with increased cell death. The molecular mechanisms by which A20 performs these diverse functions are incompletely understood, but are likely to involve the regulation of ubiquitindependent signalling complexes (see below). A20 cleaves polyubiquitin chains, thereby exhibiting DUB activity 15, [20] [21] [22] , but also collaborates with ubiquitin activating E1 enzymes and ubiquitincarrier E2 proteins to build ubiquitin chains, thus displaying E3 ubiquitin ligase activity 22 . Furthermore, A20 directly binds to ubiq uitin chains 23, 24 . Therefore, A20 interfaces with and modi fies ubiquitylated protein substrates in multiple ways and probably uses a variety of biochemical mechanisms to regulate NFκB and celldeath signals (see below).
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Lymphoma mutations
In this Review, we examine recent studies in three areas. First, human genetic studies have linked both germ line polymorphisms and somatic mutations of TNFAIP3 (which encodes A20) to inflammatory and malignant human diseases. Second, new strains of mice bearing lineagespecific deletions of Tnfaip3 have revealed several cell typespecific functions for A20. Third, biochemical studies have revealed complex mechanisms by which A20 regulates a variety of ubiquitindependent signal ling pathways in immune cells. Taken together, these studies are revealing a diverse set of genetic, cellular and molecular mechanisms by which A20 prevents disease. Other diseaseassociated TNFAIP3 SNPs are located out side of the coding regions, suggesting that they may also confer susceptibility to disease by reducing A20 expres sion 35, 44 . Importantly, mice expressing reduced levels of A20 develop spontaneous inflammation, providing direct evidence that reduced A20 expression causes autoimmune or inflammatory disease 18, 19, 43 . Figure 1 | Polymorphisms or mutations in TNFAIP3 and human diseases. The figure shows a schematic of the TNFAIP3 gene locus, which encodes A20. Exons encoding the amino-terminal OTU domain are shown in orange and exons encoding the carboxy-terminal zinc fingers (ZFs) of A20 are shown in green. The C103, ZF4 and ZF7 motifs are highlighted. Non-coding exons, including AT-rich sequences at the end of exon 9, are shown in brown. Human germline single-nucleotide polymorphisms (SNPs) in the TNFAIP3 locus that are associated with autoimmune and autoinflammatory diseases are indicated (labelled with their reference SNP (rs) numbers) , as are somatic mutations that have been identified in the coding exons of TNFAIP3 in human B cell lymphomas [50] [51] [52] [53] [54] .
A20: a protein linked to multiple human diseases
Potential benefits of correlating SNPs in specific genes with genetically complex human diseases include the ability to associate genotypes and/or molecular phenotypes with prognostic or therapeutic responses. TNFAIP3 polymorphisms and altered A20 expression have been correlated with therapeutic responses to TNF blockade in the treatment of rheumatoid arthritis, inflammatory bowel disease and psoriasis [47] [48] [49] . Moreover, the presence of certain TNFAIP3 SNPs strongly cor relates with the risk of severe renal or haematological complications in patients with SLE
31
. Therefore, in addi tion to providing insights into the pathogenesis of these inflammatory disorders, further genetic analyses might link TNFAIP3 polymorphisms with distinct subtypes of these diseases.
In addition to the effects of germline polymorphisms of TNFAIP3 in conferring susceptibility to inflamma tory diseases, biallelic somatic mutations of this gene are pathogenic in human lymphomas, suggesting that A20 acts as a tumour suppressor [50] [51] [52] [53] [54] . Biallelic mutations in the coding sequence of TNFAIP3 have been identified in ~18% of B cell lymphomas, including diffuse large B cell lymphoma, mucosaassociated lymphoid tissue type lymphoma and Hodgkin's lymphoma 50, 51 . Such muta tions occur throughout the TNFAIP3 gene and result in the introduction of stop codons, frame shifts, amino acid changes or splicing alterations 55, 56 (FIG. 1) . The expression of TNFAIP3 may also be inhibited by epigenetic methyla tion of its promoter 53, 57 . The degree to which mutations affect A20 protein stability and/or function has yet to be determined for most lymphomas.
TNFAIP3 mutations are likely to be pathogenic in cancerous transformation, as reexpressing A20 in tumour cells induces apoptosis or cellcycle arrest 50, 51, 53, 54 . As A20 deficiency can lead to exaggerated NFκB sig nalling and/or increased cell death, and as enhanced NFκB signalling is linked to several types of human B cell lymphoma, A20mediated restriction of this crucial signalling cascade may explain the tumoursuppressive function of A20 in B cells. In addition, whether A20 inac tivation contributes to other cancer cell types or predicts responses to therapies warrants further investigation. In summary, polymorphisms and mutations of TNFAIP3 have an impact on a wide range of human diseases. These links to human disease provide a compelling rationale for further investigations into the mechanisms by which A20 regulates immune cell functions.
Cellular mechanisms of A20 and disease A20 is expressed by virtually all cell types, which complicates our understanding of the physiological functions of A20 and its roles in preventing disease. In addition, A20regulated signals, such as canonical NFκB signals and cellsurvival signals, are shared by multiple ligands and cell types. Given the pleiotropic functions of NFκB and celldeath signalling in various cell types that contribute to autoimmune and inflam matory diseases, the regulation of these signalling cas cades by A20 may contribute to disease pathogenesis (TABLE 1) . However, the multiorgan inflammation and perinatal lethality of A20deficient mice largely prevents detailed studies of the functions of A20 in adult mice 14 . The recent development of mice with conditionally tar geted Tnfaip3 alleles (Tnfaip3 flox/flox mice) has enabled lineagespecific and temporally controlled deletions of Tnfaip3, thereby facilitating studies of the functions of A20 in specific immune cell types.
B cell-mediated autoimmunity and lymphomas. The genetic association of TNFAIP3 SNPs with SLE and of somatic TNFAIP3 mutations with B cell lympho mas suggests that A20 might have important functions 
Activation-induced cytidine deaminase
(AID). An enzyme that is required for two crucial events in the germinal centre: somatic hypermutation and class-switch recombination.
in B cells. The expression of A20 is transcriptionally induced in B cells and may also be regulated at the posttranslational level via cleavage by the paracaspase MALT1 (REFS 9,58,59). Insights into how A20 regulates B cell functions have emerged from studies of mice lack ing A20 specifically in B cells (Tnfaip3 flox/flox Cd19Cre mice). Three independent groups have generated such mice 18, 19, 60 , and the phenotypes of these mice are largely similar.
A20deficient B cells display exaggerated NFκB mediated responses and are hyperresponsive to multiple stimuli, including lipopolysaccharide (LPS) and B cell receptor (BCR) and CD40 ligation. They pro duce higher levels of IL6 following stimulation than wildtype B cells, which may account for the moder ate increase in the number of A20sufficient T cells in Tnfaip3 flox/flox Cd19Cre mice. As these mice age, a pro gressive increase in spontaneous B cell activation, the expansion of myeloid cell populations and plasma cell hyperplasia are observed 18, 19 . In addition, the expression of A20 in B cells may be important for the development of marginal zone B cells 19, 60 .
Tnfaip3
flox/flox Cd19Cre mice spontaneously develop an autoimmune condition similar to SLE that is char acterized by elevated numbers of plasma cells and ger minal centre B cells, IgM and IgG autoantibodies, and renal immunoglobulin deposits 18, 19, 60 . These phenotypes are observed by 3-4 months of age, suggesting that A20 expression in B cells might prevent an early step in SLE pathogenesis. Although Tnfaip3 flox/flox Cd19Cre mice were not shown to develop renal failure, the severity of the clinical disease in these mice may be more apparent when they are bred onto lupusprone backgrounds.
The increase in the number of germinal centre B cells in Tnfaip3 flox/flox Cd19Cre mice may be due to the resistance of A20deficient B cells to FASmediated apoptosis 18 . This resistance may be mediated by the markedly elevated levels of NFκBdependent anti apoptotic proteins, including B cell lymphoma X (BCLX), in stimulated A20deficient B cells. This finding was somewhat surprising given the increased sensitivity of A20deficient fibroblasts and thymocytes to TNFmediated programmed cell death 14 . Thus, the regulation of cell survival or death by A20 is likely to be dependent on both the cell type and the context 61 . Focused genetic studies -including deep sequencing of the human TNFAIP3 gene -have revealed that a SNP in the 3′ noncoding region confers susceptibility to SLE by reducing A20 expression 31 . The spontaneous devel opment of autoantibodies in heterozygous Tnfaip3 +/− mice may thus genetically mimic the human condition (G. E. Hammer and A.M., unpublished observations). Furthermore, heterozygous Tnfaip3 flox/+ Cd19Cre mice, which express reduced levels of A20 in B cells, also con tain increased numbers of germinal centre B cells and develop autoantibodies 18 . In contrast to many mouse models of autoimmune disease in which homozygous null alleles are used to approximate human heterozygous SNPs, mice with spontaneous SLElike disease owing to reduced A20 expression may provide a closer genetic approximation to the human condition.
The increased NFκB signalling and enhanced sur vival of A20deficient germinal centre B cells also provide a potential molecular underpinning for the role of A20 in preventing human B cell lymphomas. Several human B cell lymphoma subtypes are thought to arise from ger minal centre B cells, and dysregulated NFκB signalling is a known feature of the oncogenic mutations in these cells. A failure to eliminate germinal centre B cells could also lead to prolonged activation-induced cytidine deaminase (AID) activity and increased numbers of somatic muta tions, including oncogenic mutations. Thus, the effects of exaggerated NFκB signalling in causing increased expres sion of antiapoptotic proteins and resistance to cell death suggest several ways in which A20 deficiency may con tribute to the transformation of germinal centre B cells. Although mice bearing A20deficient B cells have not yet been shown to spontaneously develop B cell lymphomas, future studies of potentially collaborative oncogenes may better define the tumoursuppressor functions of A20.
In summary, A20 regulates the homeostasis of germi nal centre B cells and marginal zone B cells. In addition, important roles for A20 in other B cell subtypes may become apparent with the generation of mice that lack A20 expression in B cells at other stages of their devel opment. Nevertheless, the studies to date indicate that precisely regulated A20 expression levels in B cells are essential for preventing B cellmediated autoimmunity and B cell malignancies in mice and humans.
Dendritic cells and immune homeostasis.
Early physi ological evidence for the importance of A20 in regu lating innate immune responses emerged from the observation that mice deficient in both A20 and recombinationactivating gene 1 (RAG1; which is required for the development of B and T cells) develop myeloid celldependent inflammation, cachexia and perinatal lethality in a similar manner to A20deficient mice 14 . In addition to restricting TNFinduced NFκB signals, A20 has been shown to restrict NFκB sig nals triggered by both TLRs and NLRs [14] [15] [16] Mice in which A20 expression is specifically ablated in keratinocytes (Tnfaip3 flox/flox Krt14Cre mice) exhibited keratinocyte hyperproliferation, dishevelled hair and sebocyte hyperplasia 73 . These phenotypes were consist ent with dysregulated ectodysplasin A receptor (EDAR) mediated signalling, and in vitro studies suggested that A20 can inhibit EDARtriggered NFκB signalling in a manner independent of its DUB activity 73 . No spontane ous inflammation was observed in these mice, suggesting that A20 does not restrict basal proinflammatory signals in keratinocytes. Alternatively, cylindromatosis protein (CYLD), another DUB, might partly compensate for the loss of A20 expression and prevent exaggerated NFκB signalling activity in these cells under steadystate con ditions. CYLD is highly expressed in the skin, and muta tions in this gene cause the skin disease cylindromatosis 74 . Compensation for the loss of A20 by CYLD would also be consistent with the ability of CYLD to remove ubiquitin chains from proteins similar to those deubiquitylated by A20 (REF. 75 ). Given the crucial roles of A20 in restricting NFκB signals, challenging Tnfaip3 flox/flox Krt14Cre mice with proinflammatory ligands might reveal whether A20 expression by keratinocytes restricts the duration or intensity of skin inflammation.
A20 and endothelial cells. A20 was originally cloned from endothelial cells, and heterologous expression of A20 in endothelial cells suppresses inflammation in neighbouring tissues (including transplanted tis sues) [76] [77] [78] . The role of A20 in endothelial cells might also contribute to links between human TNFAIP3 poly morphisms and vascular disease; for example, SNPs in TNFAIP3 are associated with increased atherosclerotic disease in patients with type 2 diabetes 44 (FIG. 1) . In addi tion, a genomewide screen for genes regulating suscep tibility to atherosclerosis in apolipoprotein Edeficient mice identified a mutation in the coding sequence of Tnfaip3, and transgenic expression of A20 reversed this susceptibility 79, 80 . One pathophysiological sug gestion from these studies was that A20 expression in endothelial cells might suppress the expression of adhe sion proteins for monocytes at sites of atherosclerotic plaque formation. Given the emerging evidence that type 2 diabetes and atherosclerosis are associated with chronic low levels of inflammation in humans, the anti inflammatory functions of A20 may help to prevent these diseases. Endothelial cellspecific deletion of Tnfaip3 may provide further insight into these issues.
The studies above indicate that the level of A20 expression in specific cell types influences the type of inflammation that occurs in vivo and the susceptibility to inflammatory diseases. Reduced A20 expression in several cell types may thus collaborate with additional genes or environmental triggers to define disease pheno types (TABLE 1) . Moving forward, analyses of mice with reduced or absent expression of A20 in other specific cell types (such as T cells) or combinations of cell types (such as both B and T cells) should provide new insights into disease pathologies and potential therapeutic strategies. A20: biochemical mechanisms of action A20 and the regulation of ubiquitin-dependent signalling. The A20 protein exhibits DUB, E3 ubiquitin ligase and ubiquitinbinding activities in cellfree and cellular systems (FIG. 2) . Its DUB activity is mediated by an amino terminal motif containing a catalytic cysteine residue Figure 2 | Biochemical characteristics of A20 protein function. The de-ubiquitylating (DUB) activity of A20 is mediated by the catalytic cysteine at position 103 (C103) within the OTU domain. A20 also contains seven zinc fingers (ZFs), which mediate its E3 ubiquitin ligase activity (via ZF4) and its ubiquitin-binding activity. Indeed, A20 binds to ubiquitylated E2 enzymes such as UBCH5A via ZF4-ZF7, to K63-linked polyubiquitin chains via ZF4 (REF. 23) and to linear polyubiquitin chains via ZF7 (REFS 24, 90, 91) . A20 also interacts with substrates such as receptor-interacting protein 1 (RIP1) via ZF1-ZF3 (with ZF1 being crucial for binding) 22, 23 , with E3 enzymes such as TNFR-associated factor 6 (TRAF6) via the OTU domain, and with ubiquitin-binding proteins such as TAX1-binding protein 1 (TAX1BP1), IκB kinase-γ (IKKγ), A20-binding inhibitor of NF-κB activation 1 (ABIN1) and ABIN2 via the ZF domain. Some of these latter interactions may occur through the mutual binding of A20 and the interacting protein to ubiquitin chains. The regions that mediate the interaction of A20 with the E3 enzymes RING-finger protein 11 (RNF11) and ITCH, as well as with itself, have not been clearly defined. In addition to their other functions, the C103 and ZF4 motifs have been shown to support the degradation of E2 enzymes 81 . A20 also undergoes post-translational modifications; for example, a site of A20 phosphorylation by IKKβ is indicated. Human A20 is cleaved by the paracaspase MALT1 at the site indicated by an asterisk. The site at which mouse A20 is cleaved has not been precisely determined, but the region where it is cleaved is indicated by a bracket.
Cellular inhibitor of apoptosis
A family of proteins (comprising cIAP1, cIAP2, XIAP and NAIP) that contain a BIR domain and that can act as E3 ubiquitin ligases and as inhibitors of caspases.
(C103) in its OTU domain, whereas zinc finger 4 (ZF4) in the carboxyterminal domain of A20 binds ubiquitin and supports E3 ubiquitin ligase activity 15, 22, 23, 81, 82 . These biochemical roles -considered together with emerging evidence of the crucial roles of ubiquitylation in regu lating protein-protein interactions, protein stability and intracellular signals -suggest that A20 regulates intra cellular signals by regulating ubiquitylated signalling complexes.
The attachment of polyubiquitin chains to signalling proteins stimulates the recruitment of ubiquitinbinding proteins. The attachment of K48linked polyubiquitin chains has long been known to target proteins for protea somal degradation, whereas polyubiquitin chains linked via other lysine residues, such as K63linked chains, can recruit downstream signalling proteins, thereby propa gating signals. The DUB activity of A20 cleaves anchored K63linked polyubiquitin chains, so this biochemical function may help to restrict ubiquitindependent sig nals. During TNF signalling, the conjugation of receptor interacting protein 1 (RIP1; also known as RIPK1) with K63linked polyubiquitin chains leads to the recruit ment of the signalling molecules TAK1binding pro tein 2 (TAB2), TGFβactivated kinase 1 (TAK1) and IκB kinaseγ (IKKγ; also known as NEMO) to form a complex with RIP1. This in turn leads to the phospho rylation of NFκB inhibitorα (IκBα) and the activation of NFκB 4 . The increased ubiquitylation of RIP1 in stim ulated A20deficient cells indicates that A20 is crucial for restricting RIP1 ubiquitylation 22 (FIG. 3) . In this context, the DUB activity of A20 probably restricts TNFinduced NFκB signalling by removing K63linked polyubiquitin chains from RIP1.
The assembly of K63linked polyubiquitin chains also supports TNFRassociated factor 6 (TRAF6) mediated activation of NFκB during IL1R and TLR signalling, and the removal of these chains by A20 may be a mechanism by which A20 restricts TLR sig nals 4, 15, 17, 20, 83, 84 (FIG. 3) . Furthermore, A20restricts the ubiquitylation of RIP2 (also known as RIPK2) during NOD signalling 16 and the ubiquitylation of TBK1 and IKKε (also known as inducible IKK) during double stranded RNAinduced signalling 85 , which suggests other potential targets for the DUB activity of A20 (FIG. 3) . A20 also restricts NFκB signalling triggered by the T cell receptor (TCR), BCR and CD40, so A20 may also deubiquitylate targets in these pathways 9, 18, 19, 86 . These studies are consistent with the notion that the DUB activity of A20 restricts cellular activation signals by cleaving activating K63linked polyubiquitin chains from target signalling proteins.
In addition to limiting ubiquitylation by cleaving polyubiquitin chains, A20 has been shown to inhibit ubiquitin chain synthesis by interfering with E2-E3 binding 81 . A20 inhibits the interactions of the E2 enzymes UBCH5C and UBC13 with TRAF2 and cellular inhibitor of apoptosis (cIAP) proteins, which are RINGfinger E3 ubiquitin ligases 81 . These findings sug gest that A20 could inhibit multiple E2-E3 combina tions, and hence a broad array of ubiquitylation events. Whether A20 restricts substrate ubiquitylation by cleaving polyubiquitin chains or by inhibiting ubiquitin ligase activity, the restriction of the ubiquitylation of sig nalling proteins appears to be an important mechanism by which A20 regulates immune signals.
Several questions concerning the DUB activity of A20 remain. First, A20 selectively cleaves unanchored K48linked polyubiquitin chains (that is, free chains that are not covalently attached to signalling proteins), but not K63linked polyubiquitin chains, to mono ubiquitin 20, 21 . However, A20 removes K63linked polyubiquitin chains from TRAF6. It does this with out disassembling the chains, but rather by cleaving the entire polyubiquitin chain at the ubiquitin-TRAF6 junction 20 . Although recombinant A20 exhibits these specificities in vitro, the physiological targets of A20 in cells are incompletely defined, and it may collaborate with other proteins to define target specificity. Second, the C103 motif of A20 appears to be required for A20 to destabilize E2 enzymes and inhibit E2-E3 inter actions 81 . However, it remains to be determined how the DUB activity of A20 would support the ubiquitylation and degradation of E2 enzymes. Another OTU domain containing protein, otubain 1, uses residues other than the catalytic cysteine to inhibit the function of E2 enzymes, so it is possible that A20 utilizes its OTU domain in this manner 87 . Third, it is currently unclear how the DUB activity of A20 overlaps with that of other DUBs (such as CYLD) that target similar substrates. Such DUBs could remove different types of ubiqui tylation chain from common substrates. Alternatively, distinct DUBs could target the same ubiquitylated sub strates in distinct cell types, after distinct stimuli or at different times after ligand binding. Future biochemi cal studies aimed at better understanding how differ ent ubiquitin chains are targeted for deubiquitylation, together with genetic studies aimed at understanding the epistatic relationships between distinct DUBs, could begin to shed light on this issue. Finally, as the DUB activity of A20 clearly depends on its catalytic C103 resi due, the physiological role of this DUB activity could be clarified by using knockin mice expressing A20 proteins mutated at C103. A20 also regulates cell death. The roles of A20 in reg ulating cell survival are complex, and may be cell type specific, as A20 inhibits TNFinduced death in fibro blasts but supports FASmediated death in activated B cells 14, 18 . The antiapoptotic functions of A20 are not likely to be secondary to decreased NFκB signalling, as more A20deficient fibroblasts die in the presence of cycloheximide (which abrogates NFκBdependent protein synthesis), and NFκBdependent genes tend to have antiapoptotic functions. The molecular mecha nisms by which A20 inhibits apoptosis are incompletely understood but may involve A20 deubiquitylating an activated, ubiquitylated form of caspase 8 (REF. 88 ). By contrast, the mechanism by which A20 supports cell death in activated B cells may involve A20 inhibiting NFκBdependent expression of the antiapoptotic protein BCLX. The cell deathregulating functions of A20 add an important additional dimension to the A20mediated regulation of proinflammatory NFκB Nature Reviews | Immunology signals, as the survival of immune cells and stromal cells has distinct effects in inflammatory, autoimmune and infectious diseases. How the antiinflammatory and cell deathregulating functions of A20 are integrated in vivo and in specific cell types will be an important area of future investigation.
In addition to the Nterminal DUB motif, the Cterminal domain of A20 probably has crucial roles in regulating ubiquitindependent signals (FIG. 2) . The Cterminal domain contains seven zinc fingers, and early studies showed that enforced expression of this domain inhibits NFκB signalling 89 . More recent studies Figure 3 | A20-dependent regulation of ubiquitin-dependent signalling pathways. A20 regulates multiple ubiquitindependent innate immune signalling cascades, including those downstream of tumour necrosis factor receptor 1 (TNFR1), interleukin-1 receptor (IL-1R), Toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain (NOD) proteins. During these signalling cascades, E2 enzymes, such as UBCH5 and UBC13, and E3 ligases, such as cellular inhibitor of apoptosis (cIAP) proteins, TNFR-associated factor 6 (TRAF6), and perhaps TRAF2, collaborate to build polyubiquitin chains. These polyubiquitin chains can be K48-linked, K63-linked or joined by other linkages, and are attached to substrates such as receptor-interacting protein 1 (RIP1), TRAF6, IκB kinase-γ (IKKγ) and RIP2. A distinct enzymatic complex known as LUBAC (linear ubiquitin chain assembly complex) builds linear polyubiquitin chains on RIP1 and IKKγ 116, 117 . In addition, unanchored ubiquitin chains (that is, chains that are not covalently attached to signalling proteins) are integral to these cascades. A20 may regulate these signalling complexes by cleaving K63-linked ubiquitin chains from RIP1, TRAF6 and/or IKKγ through the de-ubiquitylating (DUB) activity of its OTU domain. A20 can also regulate these signalling pathways by supporting the degradation of the E2 enzymes UBCH5 and UBC13, thereby inhibiting E3 ligase activity that is dependent on these E2 enzymes. Finally, A20 can build K48-linked polyubiquitin chains on RIP1, which leads to its degradation. In addition, the ZF4 and ZF7 domains of A20 have been shown in vitro to bind to K63-linked ubiquitin chains and linear ubiquitin chains, respectively, on IKK complexes and TNFR complexes and may use these interactions to facilitate the inhibition of these signalling complexes. Although it is not shown in the figure, the ubiquitin-binding activities of A20 might also compete with those of other ubiquitin-binding proteins and/or help A20 to function as an adaptor protein for other regulators, such as A20-binding inhibitor of NF-κB activation 1 (ABIN1), ITCH, RING-finger protein 11 (RNF11) or TAX1-binding protein 1 (TAX1BP1). In addition to restricting TNFR, IL-1R, TLR and NOD signals, A20 regulates signals triggered by the T cell receptor 9 (not shown) and CD40 (not shown). Finally, A20 restricts TNF-induced apoptosis, possibly by restricting the ubiquitylation of caspase 8 (REFS 14, 88) (not shown). IRAK, IL-1R-associated kinase; LPS, lipopolysaccharide; MDP, muramyl dipeptide; NF-κB, nuclear factor-κB; TAB, TAK1-binding protein; TAK1, TGFβ-activated kinase 1; TRADD, TNFR1-associated death domain protein; ZF, zinc finger.
revealed that ZF4 functions as an E3 ligase, supporting the K48linked ubiquitylation and proteasomal degra dation of RIP1 (REF. 22) (FIG. 3) . The evidence that A20 both disassembles K63linked polyubiquitin chains and builds K48linked chains suggests that these two enzy matic functions would result in the deactivation and degradation of RIP1, thereby terminating the role of this signalling molecule in propagating TNFinduced NFκB signalling. These findings also raise interesting ques tions regarding whether and how these two biochemical activities might be coordinated. For example, K63linked polyubiquitin chains might be exchanged for K48linked chains in a synchronized ubiquitinediting process on a single lysine residue in RIP1 (FIG. 3) .
The ZF4 motif of A20 also binds directly to ubiqui tin chains and supports the binding of A20 to ubiquity lated E2 enzymes 23 . Combined with the ability of A20 to bind to RIP1, this interaction could help to explain how ZF4 supports the ubiquitylation of RIP1. Interestingly, the ZF4 motif was also shown to be required for A20mediated inhibition of E2-E3 interactions in cells 81 , implying that the ZF4 motif can inhibit ubiquitylation. Thus, the ZF4 motif might support or restrict ubiqui tylation in distinct contexts. It also remains possible that the ZF4 motif of A20 performs an E3 ubiquitin ligaseindependent function. As with the catalytic C103 residue, the physiological importance of ZF4 in regulat ing various cell signals and immune functions should become clearer with genetic interrogation of this motif via targeted mutation of ZF4.
Recent experiments indicate that the ZF7 motif of A20 also regulates NFκB signalling by directly restrict ing the TAK1dependent activation of IKKγ
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. This activ ity is mediated via the binding of the ZF7 motif to linear ubiquitin chains 90, 91 (FIG. 3) . The presence of truncated mutants of A20 lacking ZF7 in B cell lymphomas rein forces the importance of this motif. Thus, A20 may use several biochemical activities to regulate ubiquitylated signalling complexes. These observations raise interest ing questions regarding how the functions of the C103, ZF4 and ZF7 motifs collaborate to restrict NFκB signals. For example, in other proteins, spatially separated ubiq uitinbinding motifs recognize distinct conformations of polyubiquitin chains through multipartite inter actions 92, 93 , so the multiple ubiquitinbinding motifs in A20 may col laborate to recognize substrates bearing specific ubiqui tin chains. In addition, the other five zinc fingers of A20 may have important functions complementary to those of ZF4 and ZF7. The complex biochemical mechanisms by which A20 regulates ubiquitylated signalling proteins provide clues as to how ubiquitindependent signals are generally regulated and also suggest novel approaches for the therapeutic manipulation of these signalling cas cades through the targeting of these motifs. For exam ple, selective inhibition of the C103based DUB activity or the ZF4 or ZF7based ubiquitinbinding motifs of A20 might preferentially affect the regulation of TNF induced versus TLRinduced NFκB signals. In addition, selective inhibition of A20 interactions with K63linked versus linear ubiquitin chains may favour distinct ubiquitindependent signals.
A20 and the collaborative regulation of ubiquitindependent signals. Several lines of evidence suggest that A20 may collaborate with other proteins to regulate cell activation and survival signals. A20 physically interacts with several proteins that bind to ubiquitin, including A20 itself, A20binding inhibitor of NFκB activation 1 (ABIN1; also known as TNIP1), ABIN2 (also known as TNIP2), TAX1binding protein 1 (TAX1BP1) and IKKγ. In addition, A20 interacts with various proteins that function directly or collaboratively as E3 enzymes, such as TRAF2, TRAF6, cIAP1, cIAP2, ITCH and RINGfinger protein 11 (RNF11) 12, 13, [94] [95] [96] [97] [98] (FIG. 2) . The overlapping effects on TNF signalling in cells lacking several of these proteins suggest that these interactions may be physiologically relevant. Complexes containing various combinations of these proteins could recognize diverse ubiquitylated signalling proteins and modify them in tandem with E2 enzymes. How each of these proteins collaborates with A20 to regulate cell signals and immune responses is poorly understood, but bio chemical and genetic tools are emerging to address these questions.
ABIN1 was identified as a binding partner of A20 via a yeast twohybrid experiment, and enforced expression of ABIN1 suppresses TNFinduced NFκB signals 12 . ABIN1 appears to cooperate with A20 to inhibit TRAF3dependent signals that lead to type I IFN production 85 . ABIN1 deficiency in mice leads to late embryonic lethality and TNFdependent cell death, demonstrating that ABIN1, similarly to A20, preserves perinatal survival and restricts TNFinduced cell death 14, 99, 100 . ABIN1deficient mice that survive to adulthood develop spontaneous autoimmunity and inflammation, a phenotype grossly resembling that of A20deficient mice 100 . Thus, ABIN1 and A20 are both crucial for preserving immune homeostasis in adult mice. Part of this antiinflammatory function may be due to the restriction by ABIN1 of MYD88dependent TLR signalling and NOD2 signalling -functions that are again shared with A20 (REFS 16,17,100). ABIN1 has also recently been shown to restrict the TLRinduced expression of CCAAT/enhancerbinding protein (C/EBP)dependent genes rather than NFκB dependent genes 101 . Hence, ABIN1 binds to A20 in cells, and ABIN1 deficiency resembles A20 deficiency in several regards. However, it remains to be deter mined whether and how A20 and ABIN1 collaborate to regulate cell signalling.
Similarly to polymorphisms of TNFAIP3, poly morphisms of TNIP1 (the gene encoding ABIN1) are strongly linked with susceptibility to SLE 28,102 and pso riatic arthritis 103 . Attempts to establish epistatic rela tionships between human SNPs in the genes encoding A20 and ABIN1 have not yet been successful, but the power to detect such associations may be limited by clinical variables and genetic haplotypes. Additional similarities between the functions of A20 and ABIN1 in human cells are suggested by the presence of somatic mutations in TNIP1 in human lymphomas 104, 105 . Thus, ABIN1 may share the tumoursuppressive function of A20 in human lymphocytes.
Little is known about the biochemical functions of ABIN1. Unlike A20, ABIN1 does not have recogniz able DUB or ubiquitin ligase motifs and is not known to exhibit enzymatic ubiquitinmodifying functions. As ABIN1 binds to polyubiquitin chains with high affinity, one model for how A20 and ABIN1 collab orate is that ABIN1 binds to both ubiquitylated sig nalling proteins and A20, thereby bringing A20 into close proximity with its ubiquitylated targets 101, 106 . This adaptor function could provide a biochemical underpinning for the biological similarities observed in A20 and ABIN1deficient animals, as well as for the correlation of SNPs in the genes encoding A20 and ABIN1 with susceptibility to SLE, psoriasis and other diseases 28, 38, [102] [103] [104] [105] . An alternative model for ABIN1 func tion is suggested by the observation that ABIN1 and IKKγ contain similar ubiquitinbinding motifs 94, 99, 106 . ABIN1 might thus compete with IKKγ for binding to polyubiquitin chains in activated signalling com plexes. As the recruitment of IKKγ is essential for the propagation of most canonical NFκB signals, ABIN1mediated displacement of IKKγ from sig nalling complexes could inhibit NFκB signalling. A20 also binds to ubiquitin chains with high affin ity, although A20 uses ubiquitinbinding motifs that are distinct from the motif used by ABIN1. Whether and how A20 may also compete with IKKγ for ubiq uitin binding, and whether such competition involves ABIN1, remains to be determined. Further definition of the types of ubiquitin chain involved and the spe cific functions of these ubiquitinbinding motifs are needed to address these issues.
In addition to binding to ABIN proteins, A20 inter acts with various other proteins, including TRAF2, TRAF6, ITCH, RNF11 and TAX1BP1 (REFS 12, 13, (94) (95) (96) (97) (98) (FIG. 2) . The phenotypes of mice and cells lacking these proteins partially overlap with the phenotypes of A20 and ABIN1 deficiency 14, 100, [107] [108] [109] [110] [111] , and TAX1BP1, RNF11 and ITCH have been shown to support A20 function during TNF and TLR signalling 85, 99, 111, 112 . Intriguingly, all of these proteins bind to ubiquitin and/or help to build ubiquitin chains. It remains to be determined how A20 interacts with these proteins, whether they collaborate in a single complex or in multiple com plexes, and how they regulate ubiquitylated signalling complexes. Nevertheless, it is likely that A20 functions in larger ubiquitinediting protein complexes that have a high degree of specificity and regulation.
Therapeutic implications of A20 biology
The broad (and growing) links between polymorphisms in TNFAIP3 and inflammatory and malignant diseases suggest that aberrant A20dependent signals are patho genic in many conditions. Loss of A20 function is directly implicated in the pathogenesis of human lymphomas, and reduced A20 function or expression has been linked with susceptibility to SLE in humans. Reduced or absent expression of A20 also causes spontaneous inflammatory and autoimmune diseases in mice. The direct correla tion of hypomorphic A20 expression with both human and experimental diseases argues that such mouse mod els are excellent models for understanding the role of A20 in human disease. Moreover, this correlation sug gests that increasing the expression and/or function of A20 is a promising therapeutic strategy. One indication of the potential of A20 as a buttress against destructive inflammation is the resistance to experimental colitis observed in mice with enforced A20 expression in IECs, which has no apparent effect on normal intestinal func tion 72 . In the case of B cell lymphomas, reexpression of A20 is directly cytotoxic for human B cell lymphomas bearing TNFAIP3 mutations but does not affect cell lines with intact A20 loci and normal NFκB expres sion 51 . The challenge for finding effective therapies is to devise strategies that enhance A20 expression. As cur rent therapeutic approaches based on antibodies or small molecules are more effective in reducing the functions of proteins rather than restoring them, targeting proteins that inhibit A20 function could be a more tractable, if somewhat indirect, therapeutic approach. Recent studies have identified microRNAs that target TNFAIP3 mRNA, so inhibition of these microRNAs could enhance A20 expression [113] [114] [115] . Regardless of the approach, the genetic links between SNPs in TNFAIP3 and rheumatoid arthri tis, SLE, psoriasis, coeliac disease, Crohn's disease, type 2 diabetes, atherosclerosis and lymphomas -as well as the potential use of A20 modulation in vaccine development and transplantation 63-65,76-78 -suggest that approaches that either enhance or suppress A20 expression may be promising arenas for therapeutic development. 
